Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT04237649 Terminated - Solid Tumors Clinical Trials

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Start date: February 20, 2020
Phase: Early Phase 1
Study type: Interventional

The primary objective of the trial was to characterize the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose (RD) for expansion of single agent KAZ954 and KAZ954 in combination with PDR001, NIR178 and NZV930.

NCT ID: NCT04237337 Not yet recruiting - Multiple Sclerosis Clinical Trials

Drugs for the Treatment of Multiple Sclerosis and Risk of Cancer: a Pharmacovigilance Analysis in Vigibase

PVSEPK
Start date: January 2020
Phase:
Study type: Observational

Even though the therapeutic panel for multiple sclerosis (MS) treatment has improved in the last 20 years, safety data especially for the second-line and innovative treatments are lacking. The association between MS and cancer has long been investigated but has led to conflicting results. No studies have reported an increased risk of cancer after long-term exposure to immuno-modulators. The present study will assess whether drugs for the treatment of MS are associated with an increased risk of cancer by analyzing the disproportionality of reports in the World Health Organization (WHO) pharmacovigilance database.

NCT ID: NCT04236414 Recruiting - Solid Tumours Clinical Trials

Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours

Start date: January 14, 2020
Phase: Phase 1
Study type: Interventional

A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents with solid tumours.

NCT ID: NCT04235101 Completed - Solid Tumor Clinical Trials

Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors

Start date: June 22, 2020
Phase: Phase 1
Study type: Interventional

SYD985.004 is a two-part phase I study with the antibody-drug conjugate SYD985 in combination with niraparib aimed at evaluating safety, pharmacokinetics and efficacy in patients with HER2-expressing locally advanced or metastatic solid tumours.

NCT ID: NCT04233567 Active, not recruiting - Cholangiocarcinoma Clinical Trials

Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

Start date: January 16, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well infigratinib works in treating solid tumors that have spread to other places in the body (advanced or metastatic) in patients with FGFR gene mutations such as FGFR1-3 gene fusions or other FGFR genetic alterations. Mutations are any changes in the genetic material (DNA) of a cell. FGFR proteins are involved in cell division, cell maturation, formation of new blood vessels, wound healing, and bone growth, development, and maintenance. FGFR mutations can cause the FGFR protein to become over-active in diseases such as cancer. Infigratinib may stop the growth of tumor cells by blocking FGFR proteins in these tumors.

NCT ID: NCT04233060 Completed - Clinical trials for Advanced Solid Tumor

A Study of CS3005 in Advanced Solid Tumors

Start date: January 10, 2020
Phase: Phase 1
Study type: Interventional

A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects with Advanced Solid Tumors

NCT ID: NCT04230772 Recruiting - Clinical trials for Colorectal Neoplasms

Clinical Outcomes of NOSES Versus Traditional Robotic-assisted Surgery for Patients With Colorectal Cancer

NOTR
Start date: February 1, 2021
Phase: N/A
Study type: Interventional

In this study, the investigators will compare the clinical outcomes of the natural orifice specimen extraction surgery versus traditional robotic-assisted surgery in the treatment of colorectal cancer.

NCT ID: NCT04230200 Active, not recruiting - Malignant Tumor Clinical Trials

Prospective Screening Programme for Malignant Tumors

Start date: March 28, 2017
Phase:
Study type: Observational

In prospective part of study, the investigators have found that the parameters of routine blood tests can differentiate varieties of malignancy from healthy people. The investigators enrolled healthy subjects and patients with malignancy that aged from 18 to 85,and collected their clinical data and blood tests result to build the model.And retrospectlly enroll healthy subjects and patients to test the model.

NCT ID: NCT04229121 Not yet recruiting - Clinical trials for Circulating Tumor DNA

Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients

Start date: January 15, 2020
Phase:
Study type: Observational

Verify the Coincidence rate between Circulating tumor cells (CTCs) and tumor tissue or Circulating tumor DNA (ctDNA) of advanced NSCLC patients with Driver gene mutation

NCT ID: NCT04228406 Recruiting - Solid Tumor Clinical Trials

Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161

Start date: July 1, 2019
Phase: Phase 1
Study type: Interventional

Safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy evaluation of the selective c-MET inhibitor GST-HG161 in patients with advanced or metastatic solid tumors: An open, single and multiple administration, dose escalation, and expanded phase I trial